首页|期刊导航|甘肃医药|乳腺癌中T细胞免疫反应的调控机制与治疗策略

乳腺癌中T细胞免疫反应的调控机制与治疗策略OA

Regulatory mechanisms and therapeutic strategies of T-Cell immune responses in breast cancer

中文摘要英文摘要

乳腺癌免疫治疗的疗效受限于其高度异质性的肿瘤微环境(TME).T 细胞作为适应性免疫的核心,其在 TME 中的功能状态决定了免疫应答的结局.本综述系统阐述了乳腺癌TME中T细胞功能亚群的多样性及其临床意义,并阐明T细胞的功能与命运受到多重机制的精密调控.主要包括以 PD-1/PD-L1 和 CTLA-4 轴为核心的免疫检查点信号以及由肿瘤细胞代谢重编程(如Warburg效应、色氨酸代谢)所引发的营养竞争与微环境酸化等.免疫检查点抑制剂(ICIs)已成为三阴性乳腺癌的标准治疗组成部分,过继性细胞疗法(如 TIL、CAR-T)展现出克服耐药的潜力,而联合疗法(如 ICIs 联合放疗、靶向 CAF、STING 激动剂)及新兴技术(如放射性配体疗法、纳米药物递送系统)正成为研究热点.未来的突破依赖于对TME动态更深入的理解,开发针对不同免疫表型的精准治疗策略,并探索有效的生物标志物以实现真正的个体化免疫治疗.

The efficacy of immunotherapy for breast cancer is limited by the highly heterogeneous tumor microenvironment(TME).T cells,as the core of adaptive immunity,dictate the outcome of immune responses through their functional state within the TME.This review sys-tematically describes the diversity of T cell functional subsets in the breast cancer TME and their clinical significance,and elucidates the multi-ple mechanisms that precisely regulate T cell function and fate.These mechanisms primarily include immune checkpoint signaling centered on the PD-1/PD-L1 and CTLA-4 axes,as well as nutrient competition and microenvironment acidification resulting from tumor cell metabolic re-programming(e.g.,the Warburg effect,tryptophan metabolism).Immune checkpoint inhibitors(ICIs)have become a standard treatment com-ponent for triple-negative breast cancer;adoptive cell therapies(e.g.,TILs,CAR-T)demonstrate the potential to overcome drug resistance;and combination therapies(e.g.,ICIs combined with radiotherapy,targeting CAFs,STING agonists)and emerging technologies(e.g.,radioligand ther-apy,nanodrug delivery systems)are becoming research hotspots.Future breakthroughs depend on a deeper understanding of the dynamics of the TME,developing precision treatment strategies targeting different immune phenotypes,and exploring effective biomarkers to achieve truly per-sonalized immunotherapy.

李多龙;赵德贤;王玮;张瑞芳;严天鑫;李新月

民勤县人民医院,甘肃 武威 733399民勤县人民医院,甘肃 武威 733399甘肃中医药大学附属医院,甘肃 兰州 730000甘肃中医药大学附属医院,甘肃 兰州 730000甘肃中医药大学附属医院,甘肃 兰州 730000甘肃中医药大学附属医院,甘肃 兰州 730000

医药卫生

乳腺癌肿瘤微环境T淋巴细胞免疫检查点抑制剂过继性细胞疗法代谢重编程联合治疗

breast cancertumor microenvironmentT cellsimmune checkpoint inhibitorsadoptive cell therapymetabolic repro-grammingcombination therapy

《甘肃医药》 2026 (5)

390-397,8

兰州市科技计划项目(编号:2024-9-74)

10.15975/j.cnki.1004-2725.2026.05.002

评论